Home
.
Site map
.
Contact us
.
Disclaimer
.
Privacy policy
About Peplin
Company profile
Company history
Corporate strategy
Products & technology
Research and development
Drug development process
Clinical development
Pre-clinical development
Research
Research programs
Publications
Abstracts
Manufacturing process
Glossary
Target diseases
Actinic keratosis (AK)
Non-melanoma skin cancer (NMSC)
Leukemia
Bladder cancer
Corporate information
Board of directors
Executive management
Corporate directory
Corporate governance
Dermatology clinical advisory board
Investor information
ASX & media releases
PEPTalk
Reports to shareholders
Annual
Half yearly
Quarterly cashflow
Share price information
Securities trading
Major shareholders
FAQs
Links
News reports
ASX and media releases
.................................................................................
Current year
|
Archived 2007
|
Archived 2006
|
Archived 2005
|
Archived 2004
|
Archived 2003
|
Archived 2002
Current year
19-Aug-08
Peplin secures approximately US$24m in additional financing
30 Kb
19-Aug-08
Peplin announces Executive Management Appointments
33 Kb
14-Aug-08
Enrolment complete in Phase IIb AK clinical trial
28 Kb
31-Jul-08
Peplin to present at Summer American Academy of Dermatology Meeting
31 Kb
25-Jun-08
Start of Phase IIb AK clinical trial
28 Kb
24-Jun-08
Scheme of arrangement tax information update
18 Kb
20-Jun-08
Appointment of interim consultant CMO
25 Kb
11-Jun-08
Peplin Investor Call
1.1 Mb
10-Jun-08
Acquisition of Neosil
24 Kb
10-Jun-08
Peplin to start Phase III under SPA agreement with FDA
30 Kb
10-Jun-08
Withdrawal of S-1
24 Kb
29-Apr-08
Chief Medical Officer resignation
19 Kb
21-Apr-08
Results of Special Meeting of Stockholders
19 Kb
25-Mar-08
Notice of Special Meeting of Stockholders
40 Kb
16-Jan-08
Results of Special Meeting of Stockholders
23 Kb
click
here
to download the Adobe reader
© Peplin 2008